With all the furore surrounding the new developments with KRAS G12C inhibitors in lung and colon cancer, it is easy to forget that there are plenty of other promising related ideas in the pipeline too. After all, there’s more than one KRAS mutation that can act as an oncogenic driver in patients that can portend poorer prognosis.

Aside from the obvious small molecules, there are other modalities to consider.

Here’s one such novel design that caught our attention — it has the potential to be elevated into an elegant platform approach with different molecules targeting a variety of critical mutations in tumour cells including KRAS G12D, which is prevalent in colon and pancreatic cancers.

I’ve had my eye on this work for a couple of years and now it’s a good time to showcase it in the spotlight given the sheer energy and attention focused on this niche…

To learn more from our oncology coverage and get a heads up on insights from our latest thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.

This content is restricted to subscribers